Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Clear out junk files and repair common Windows errors3Fix the driver behind crashes, sound loss and screen glitchesArgenx may suit investors who can tolerate biotech volatility and believe its VYVGART franchise can keep growing, but the company’s strong recent sales do not by themselves make ARGX a good buy. Its commercial business is concentrated, much of its future growth depends on clinical and regulatory execution, and the available evidence does not establish whether the shares are attractively valued. Fit depends on the price you pay, your time horizon, risk tolerance, diversification, and position size.
How does argenx make money?
argenx SE is a global immunology company whose leading commercial franchise is VYVGART (efgartigimod), a neonatal Fc receptor blocker. The company sells the medicine across multiple indications and markets; approvals and labels vary by jurisdiction. In July 2026, argenx reported that an expanded U.S. label covered all adult generalized myasthenia gravis (gMG) serotypes. The company also reported launching a self-injection prefilled syringe in 2025.
![[Brandon Turner]-The Book on Rental Property Investing- How to Create Wealth and Passive Income Through Intelligent Buy & Hold Real Estate Investing! (SoftCover)](https://m.media-amazon.com/images/I/51mMR6cQZCL._SL160_.jpg)
As an Amazon Associate I earn from qualifying purchases.
That commercial franchise is the central investment question: sales from an established product provide a different kind of evidence from a drug candidate still being tested. But a larger label or new delivery option does not guarantee patient uptake, payer access, or continued sales growth.
Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteWhat do the latest reported financials show?
The latest reported period available as of October 7, 2026, is the six months ended June 30, 2026, which argenx reported on July 23. The interim results are company-reported and unaudited. They show substantial sales, profit, and cash generation, alongside significant research spending.
#1 Best Overall
| Measure | Reported figure | Period and qualification |
|---|---|---|
| Product net sales | $4.2 billion | Full year 2025, argenx Annual Report 2025 |
| Product net sales | $2.2 billion | Full year 2024, argenx Annual Report 2025 |
| Research and development expense | $1.4 billion | Full year 2025, argenx Annual Report 2025 |
| Global product net sales | $1.5 billion; 60% year-over-year growth | Second quarter 2026, argenx’s July 23, 2026 update |
| Product net sales | $2.8 billion | First six months of 2026, argenx’s July 23, 2026 update |
| Profit | $838 million | First six months of 2026, argenx’s July 23, 2026 update |
| Operating cash flow | $0.7 billion | First six months of 2026, argenx’s July 23, 2026 update |
| Cash, cash equivalents, and current financial assets | $5.2 billion | As of June 30, 2026, argenx’s July 23, 2026 update |
| Research and development expense | $0.9 billion | First six months of 2026, argenx’s July 23, 2026 update |
The first-half figures should not be doubled to estimate a full-year result: the company has not reported that outcome, and sales and expenses can vary over time. Strong operations are relevant to the business case, but they do not determine what the shares are worth.
What could drive growth?
More use of the existing franchise
The growth case starts with continued VYVGART adoption and potential effects of label expansion. The U.S. gMG label expansion had launched by the July 2026 company update. Whether it produces additional sales depends on real-world uptake, access, distribution, and payer decisions—not just the existence of a broader label.
Rank #2
- WHAT'S INCLUDED: 110 durable (3"x5") flashcards covering all the essential aspects of fundamental analysis. Learn to analyze financial statements, key ratios, valuation metrics, and stock evaluation techniques like a pro. Plus, get 1 month of exclusive access to an online training and research platform focused on fundamental analysis for evaluating companies. Simply scan the QR code on your thank-you card to access your digital content.
- MASTER DEFINITIVE INVESTMENT PRINCIPLES, SUITABLE FOR INVESTORS AND TRADERS, Providing a Clear Roadmap for Understanding Financial Metrics and Analyzing Stocks.
- DISCOVER THE POWER OF QUICK STUDY CARDS: An Effective Alternative to Lengthy Books. They Deliver Precise, Focused Information on Financial Metrics and Stock Analysis, Making Learning Fun and Efficient for Investors and Traders.
- INSTANTLY RECOGNIZE STOCK VALUATION TRENDS AND IDENTIFY HIDDEN OPPORTUNITIES with Strategies Most Investors and Traders Overlook.
- DON'T WASTE TIME ON LOW-PROBABILITY INVESTING STRATEGIES. Focus on Learning High Probability, High Payout Strategies for Optimal Investing Success.
Other investigational programs
In its 2025 annual report, argenx described 2026 readouts planned for ocular myasthenia gravis (MG), autoimmune myositis, multifocal motor neuropathy (MMN), and primary immune thrombocytopenia (ITP), with additional readouts planned for 2027. Its July 2026 update said a myositis trial readout was expected in the third quarter of 2026. These were company-stated plans and expectations at the time, not confirmed outcomes or guarantees of approval. As of October 7, the evidence available here does not establish whether the expected readouts had occurred.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
FB102 added through the Forte acquisition
argenx completed its acquisition of Forte Biosciences on August 27, 2026, adding FB102, an anti-CD122 antibody candidate. In the acquisition announcement, argenx said it had clinical proof-of-concept data in vitiligo and celiac disease, that a Phase 2 celiac study had begun with data expected in the second half of 2026, and that a Phase 1b alopecia areata trial was ongoing. These are company-reported development details, not evidence that FB102 will succeed in later trials or become a commercial product. The acquisition broadens the pipeline while adding development and integration execution risk.
What are the main risks to weigh?
Product and customer concentration
VYVGART is argenx’s principal commercial franchise. Its half-year 2026 SEC-filed report said that approximately 72% of product net sales in the first half of the year came from three U.S. customers. Dependence on a leading product and a small number of customers can make results sensitive to uptake, distribution, access, and payer dynamics.
Clinical and regulatory uncertainty
Drug candidates can fail, encounter delays, or produce results that do not support approval. Even a positive trial does not automatically lead to a regulatory label or commercial success. Readout dates are expectations, and pipeline programs should not be treated as though they already contribute approved-product revenue.
Rank #4
- Show your trading spirit with this cool trader design. Perfect for those who love to trade stocks, bonds, and any other financial instruments.
- Anyone who loves trading stocks will surely rejoice in this trading design. Perfect for all stockbrokers, investors or anyone who loves the trading market.
- Hardcover journal with 240 line-ruled pages (120 sheets)
- Built-in elastic closure and ribbon bookmark
- Includes an expandable inner storage pocket and a pen holder
Competition, biosimilars, and pricing
argenx identifies competition, potential future biosimilar competition, government pricing laws, regulation, and market acceptance among its risks. Any of these could affect the ability to sustain sales or earn returns on development and commercialization spending.
Free tools Windows power users keep installed
One-click scans. No signup required.
Investment spending and execution
argenx reported $1.4 billion of R&D expense in 2025 and $0.9 billion in the first half of 2026. Continued research and commercial investment may support growth, but it also uses resources and requires successful execution. Cash and operating cash flow offer context for that effort; they do not eliminate the possibility of disappointing results or a changing funding profile.
Best Value
- Love trading? Are you hodling a stock? Do you hodl to the moon?! If so, this ape in a spacesuit design was made just for you. Bye, bye paper hands!
- Memestock apes, shareholders, crypto investors, and day traders will love this subtle stocks and investing design. Features a monkey in an astronaut outfit ready to go to the moon. GME FFAI MSTR BTC PEPE JASMY OPTT RKLB STONKS
- Hardcover journal with 240 line-ruled pages (120 sheets)
- Built-in elastic closure and ribbon bookmark
- Includes an expandable inner storage pocket and a pen holder
Acquisition and share-price risk
FB102’s development and commercial prospects remain uncertain, and integrating an acquired program brings additional execution risk. Argenx’s half-year 2026 report also warns that forward-looking statements are not guarantees and that its share price may be volatile. Investors should consider how a substantial decline would affect their portfolio rather than relying only on the company’s growth outlook.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Is ARGX attractively valued at the current price?
The available evidence does not establish an October 7, 2026 share price, market capitalization, valuation multiple, analyst consensus, or fair-value estimate. It therefore cannot support a conclusion that ARGX is cheap, expensive, or worth buying at a particular price. Argenx’s financial growth is not a substitute for a valuation assessment.
Before making a price-sensitive decision, check a current quote and market capitalization, then assess what expectations the share price implies. Compare the company with relevant biotech peers using consistent measures and dates, and make clear whether the comparison is based on sales, earnings, cash flow, or another measure. Consider how much future growth and pipeline success would need to materialize to justify the price. The next quarterly results were scheduled for October 22, 2026, according to the company’s financial calendar; that date was still in the future as of October 7.
Questions to ask before investing
- Can I tolerate biotech volatility? Consider whether you could hold through a sharp share-price decline, a delayed trial, or a disappointing result.
- Am I relying mainly on current sales or future pipeline success? Separate the evidence from the commercial franchise from outcomes that depend on investigational programs.
- How much concentration can I accept? Think about exposure to one leading product, a limited group of major customers, and the U.S. market.
- Does the valuation fit my assumptions? Use a current quote and explicit assumptions rather than inferring a fair price from sales growth alone.
- Is the position size appropriate? Account for your investment horizon, risk tolerance, diversification, and the possibility of losing a substantial part of the investment.
- What evidence would change my view? Decide in advance which commercial, financial, clinical, regulatory, or valuation developments would strengthen or weaken your thesis.
argenx has meaningful commercial momentum and a sizable reported liquidity position, but those strengths sit alongside product and customer concentration, ongoing R&D demands, pipeline uncertainty, and a valuation that cannot be assessed from the figures above. Whether ARGX belongs in a portfolio depends on the investor’s assumptions and circumstances, not on company growth alone.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
